CA2925757A1 - Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity - Google Patents

Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity Download PDF

Info

Publication number
CA2925757A1
CA2925757A1 CA2925757A CA2925757A CA2925757A1 CA 2925757 A1 CA2925757 A1 CA 2925757A1 CA 2925757 A CA2925757 A CA 2925757A CA 2925757 A CA2925757 A CA 2925757A CA 2925757 A1 CA2925757 A1 CA 2925757A1
Authority
CA
Canada
Prior art keywords
arg
lys
phe
dmt
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2925757A
Other languages
English (en)
French (fr)
Inventor
Hazel H. Szeto
Alexander V. Birk
Paul Szabo
Brian Yinge ZHAO
Margarita REN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CA2925757A1 publication Critical patent/CA2925757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2925757A 2013-09-30 2014-09-29 Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity Abandoned CA2925757A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361884722P 2013-09-30 2013-09-30
US61/884,722 2013-09-30
PCT/US2014/058049 WO2015048647A1 (en) 2013-09-30 2014-09-29 Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Publications (1)

Publication Number Publication Date
CA2925757A1 true CA2925757A1 (en) 2015-04-02

Family

ID=52744565

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2925757A Abandoned CA2925757A1 (en) 2013-09-30 2014-09-29 Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Country Status (7)

Country Link
US (1) US20160375088A1 (https=)
EP (1) EP3052115A4 (https=)
JP (2) JP6434523B2 (https=)
CN (1) CN106163537A (https=)
AU (2) AU2014324580B2 (https=)
CA (1) CA2925757A1 (https=)
WO (1) WO2015048647A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
WO2015095077A1 (en) * 2013-12-16 2015-06-25 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CA3020393A1 (en) * 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
CN107320711A (zh) * 2017-03-24 2017-11-07 南京大学 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用
AU2020368789B2 (en) * 2019-10-16 2024-01-18 Naturesense Co., Ltd. Peptide for improving memory and preventing or alleviating cognitive impairment, composition containing same and preparation method therefor
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307219A4 (en) * 1999-08-13 2005-04-06 Univ Columbia METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CA2947335A1 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2012271691A1 (en) * 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Also Published As

Publication number Publication date
JP6434523B2 (ja) 2018-12-05
AU2014324580B2 (en) 2020-02-27
AU2020203424A1 (en) 2020-06-11
JP2019052158A (ja) 2019-04-04
CN106163537A (zh) 2016-11-23
JP2016533392A (ja) 2016-10-27
EP3052115A4 (en) 2017-09-27
EP3052115A1 (en) 2016-08-10
AU2014324580A1 (en) 2016-04-21
WO2015048647A1 (en) 2015-04-02
US20160375088A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
US20250002530A1 (en) Aromatic-cationic peptides and uses of same
AU2020203424A1 (en) Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
US10808008B2 (en) Aromatic-cationic peptides and uses of same
JP2016000750A (ja) 芳香族カチオン性ペプチドおよびその使用
EP3049096B1 (en) Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
CA2790823A1 (en) Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3399993B1 (en) Methods for the treatment of duchenne muscular dystrophy
WO2014134562A9 (en) Methods for the treatment of mitochondrial disease
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
US20170007663A1 (en) Methods and compositions for treating and preventing cognitive dysfunction
US20220031799A1 (en) Methods and compositions for the treatment of sengers syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190903

FZDE Discontinued

Effective date: 20211213